- Sales Intelligence: Healthcare
- Posts
- Weekly Newsletter - 12.11.2024
Weekly Newsletter - 12.11.2024
Watch: Is Imposter Syndrome Sabotaging Your Team's Sales Performance?
Welcome to Sales Intelligence: Healthcare, the weekly newsletter for healthcare sales professionals. Now is the time to fine-tune your strategies, leverage cutting-edge insights, and ensure your campaigns not only engage but convert.
To ensure you continue receiving our newsletters, please add [email protected] to your contact list!


EDITOR’S PICK 🎯
Practical Tips by Kate Philpot from Getty Images
Ever felt like a fraud in a client meeting, worrying that you'll be exposed? You're not alone. Imposter syndrome can impact anyone, especially in sales, where confidence is key.
Kate Philpot, VP of Global Sales Enablement at Getty Images, and Camille Kempell, Business Development Director at Hive Perform, recently had an eye-opening conversation about overcoming self-doubt and building lasting confidence. They shared actionable strategies that go beyond managing imposter syndrome and help you build your career and maintain consistent performance.
Kate and Camille discuss:
How imposter syndrome impacts your sales confidence and performance.
Practical tips to speak up and combat self-doubt.
The power of preparation to build lasting confidence.
Why tracking your wins is essential to shifting your mindset.
How mentorship and sponsorship can fuel your growth in sales.
Want to hear more? Get all their insights now and watch the recording now 📽️

INDUSTRY INSIGHTS 🌐
The Trump administration poses significant changes for the biopharma sector, affecting healthcare policies and pharmaceutical operations. President-elect Trump's selection of cabinet members has rekindled debates surrounding healthcare. The appointment of Robert F. Kennedy Jr., an anti-vaccine advocate, as Secretary of Health and Human Services could lead to reduced support for vaccines, potentially impacting pharma giants like GSK, Pfizer, Merck, Sanofi, and AstraZeneca. Analysts predict these adjustments may shift investments away from vaccine development. Meanwhile, Mart Makary's nomination as FDA head offers stability; his conservative stance aligns with traditional Republican views, contrasting with Kennedy's unprecedented approach.
In policy remnants, Trump faces decisions on obesity medication coverage introduced by the outgoing Biden administration and the Inflation Reduction Act. While Trump himself has championed drug price negotiations, his promises to rescind IRA funding introduce uncertainties. Prospective adjustments might influence Medicare's drug pricing strategy.
Pharma marketing is on the brink of a transformative era as we approach 2025. The industry is witnessing a shift driven by technological advancements, evolving patient expectations, and heightened competition. Digital transformation is at the forefront, with companies investing in virtual health consultations, mobile apps, and online portals to enhance patient and healthcare provider engagement. This digital shift is not merely a trend but a fundamental change in how pharma marketing operates.
Patient-centric marketing is gaining traction, emphasizing the importance of understanding patient needs and preferences. By employing storytelling and personalized educational content, pharma marketers can build trust and loyalty, treating patients as partners in health. Personalized healthcare campaigns further this approach by using genetic profiling and behavioral analytics to tailor experiences, making treatment suggestions feel uniquely crafted for each individual.
Artificial Intelligence (AI) and machine learning are transforming the industry by analyzing vast datasets to predict patient needs and optimize campaigns. Social media platforms like LinkedIn and Twitter are becoming essential tools for engaging healthcare professionals and patients, offering educational campaigns and influencer collaborations to expand brand reach. Meanwhile, data-driven decision-making ensures precision and measurable results, enhancing return on investment.

INDUSTRY NEWS 📰
The U.S. bioscience industry generated $3.2 trillion in 2023, employing 2.3 million people and indirectly supporting 8 million jobs. Despite a slight slowdown, the sector resilience and innovation remain crucial for addressing global challenges, with significant growth across states and metropolitan areas.
Relmada has halted studies of its depression drug REL-1017 after failing to meet efficacy endpoints. The company is now exploring strategic alternatives, including asset sales or mergers, to maximize shareholder value. This setback highlights the challenges in developing effective treatments for major depressive disorder.
Scryb Inc. has sold its joint venture interest in Fionet Rapid Response Group (FRR Group) for CAD $3.5M, including an $800K upfront payment and a 3% royalty on net revenue until 2025. FRR’s mobile healthcare platform, already implemented nationally in Africa, will expand further under new ownership. Scryb retains rights to use FRR’s technology for non-competitive projects.

YOUR FEEDBACK MATTERS🗳️
What Did You Think of Today’s Edition? |


Sales Intelligence is a Contentive publication in the Sales & Marketing division